secwatch.observer — SEC 8-K summary
======================================

Issuer:     CorMedix Inc. (CRMD)
CIK:        0001410098
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001213900-24-041026
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CorMedix Q1 net loss $14.5M; launches DefenCath; CMS TDAPA effective July 2024
------------------------------------------------------------------------------

- Net loss of $14.5M ($0.25/sh) vs $10.6M loss ($0.24/sh) in Q1 2023; operating expenses up 44% to $15.9M.
- Cash and short-term investments $58.6M; company believes it can fund operations for at least 12 months.
- CMS granted HCPCS code and TDAPA for DefenCath effective July 1, 2024, providing 5 years of additional ESRD reimbursement.
- Commercial launch of DefenCath in inpatient setting commenced April 15, 2024; outpatient launch expected July 2024.
- Entered 5-year supply contract with ARC Dialysis; FDA meeting on DefenCath in TPN requested, feedback expected Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1410098/000121390024041026/0001213900-24-041026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1410098/000121390024041026/ea020558401-8k_cormedix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-041026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer